What problem does this paper attempt to address?

### What problem does this paper attempt to solve? This paper aims to explore the therapeutic effect and mechanism of Ac2 - 26 on acute liver injury after cardiopulmonary bypass (CPB). Specifically, the main objectives of the study are: 1. **Evaluate the impact of Ac2 - 26 on acute liver injury after CPB**: Verify through experiments whether Ac2 - 26 can improve liver dysfunction and pathological damage caused by CPB. 2. **Reveal the mechanism of action of Ac2 - 26**: In particular, whether Ac2 - 26 inhibits the inflammatory response, oxidative stress, and apoptosis through the AKT1/GSK3β/eNOS signaling pathway, thereby reducing liver injury. ### Research background Cardiopulmonary bypass (CPB) is a commonly used auxiliary method in cardiac surgery, but about 10% of patients will experience acute liver injury after the operation, which will increase the patient's mortality. Currently, it is believed that acute liver injury after CPB is mainly related to the systemic inflammatory response syndrome (SIRS) and oxidative stress. Ac2 - 26 is an active bio - peptide of Annexin A1 and has anti - inflammatory effects. It has been proven to be able to improve reperfusion injury in multiple organs. Therefore, the researchers hypothesized that Ac2 - 26 may have a protective effect on liver injury after CPB. ### Research methods To verify this hypothesis, the researchers established a rat CPB model and divided it into four groups: - **Sham - operation group (Sham)**: Only received anesthesia and intubation. - **CPB group**: Underwent standard CPB operations. - **Ac2 - 26 group (Ac)**: Injected Ac2 - 26 after CPB. - **Ac2 - 26 + AKT1 interfering RNA group (Ac/AKT1)**: Injected shRNA 72 hours before CPB to interfere with AKT1 expression, followed by CPB and injection of Ac2 - 26. By detecting liver function indicators (such as AST, ALT, LDH) in serum, inflammatory factors (such as TNF - α, IL - 1β, IL - 10), oxidative stress markers (such as XO, MPO, SOD, GSH, MDA), and pathological changes and apoptosis in liver tissue, the researchers evaluated the therapeutic effect and mechanism of Ac2 - 26. ### Main findings - **Improve liver function**: Ac2 - 26 significantly reduced the levels of AST, ALT, and LDH in serum after CPB, indicating that it has a protective effect on liver function. - **Inhibit the inflammatory response**: Ac2 - 26 reduced the expressions of pro - inflammatory factors TNF - α and IL - 1β and increased the expression of anti - inflammatory factor IL - 10. - **Reduce oxidative stress**: Ac2 - 26 decreased the levels of XO, MPO, and MDA, while increasing the activities of SOD and GSH. - **Reduce apoptosis**: Ac2 - 26 reduced the apoptosis of liver cells, as manifested by a decrease in the number of TUNEL - stained positive cells. - **Dependent on the AKT1/GSK3β/eNOS pathway**: All of these protective effects were weakened after AKT1 was interfered with, indicating that the mechanism of action of Ac2 - 26 is closely related to the AKT1/GSK3β/eNOS pathway. ### Conclusion The study shows that Ac2 - 26 can significantly improve acute liver injury after CPB by inhibiting the inflammatory response, oxidative stress, and apoptosis, and its mechanism of action mainly depends on activating the AKT1/GSK3β/eNOS signaling pathway. This finding provides a theoretical basis for the development of new treatment strategies.

Ac2-26 reduced the liver injury after cardiopulmonary bypass in rats via AKT1/GSK3β/eNOS pathway

Protective Effects of Acupuncture in Cardiopulmonary Bypass-Induced Lung Injury in Rats

Electroacupuncture Ameliorates Cardiopulmonary Bypass Induced Apoptosis in Lung Via ROS/Nrf2/NLRP3 Inflammasome Pathway

Ac2-26 activated the AKT1/GSK3β pathway to reduce cerebral neurons pyroptosis and improve cerebral function in rats after cardiopulmonary bypass

The role and mechanism of the annexin A1 peptide Ac2-26 in rats with cardiopulmonary bypass lung injury

The role of annexin A1 peptide in regulating PI3K/Akt signaling pathway to reduce lung injury after cardiopulmonary bypass in rats

The Inhibition of Bruton Tyrosine Kinase Alleviates Acute Liver Failure via Downregulation of NLRP3 Inflammasome.

Work in progress report - Cardiopulmonary bypass: Hepatic injury in a rat cardiopulmonary bypass model

Ac2-26 mitigated acute respiratory distress syndrome rats via formyl peptide receptor pathway

Ac2-26, an Annexin A1 Peptide, Attenuates Ischemia-Reperfusion-Induced Acute Lung Injury

Activation of Cyclic Adenosine Monophosphate-Dependent Protein Kinase a Signaling Prevents Liver Ischemia/reperfusion Injury in Mice

Hepatic Injury in a Rat Cardiopulmonary Bypass Model.

Ac2-26 attenuates hepatic ischemia-reperfusion injury in mice via regulating IL-22/IL-22R1/STAT3 signaling

The Liver Function Changes and Risk Factor Analysis in Patients at Peri-operative Period of Cardiopulmonary Bypass Surgery

KEAP1-NRF2 Complex in Ischemia-Induced Hepatocellular Damage of Mouse Liver Transplants

Optimized Postconditioning Algorithm Protects Liver Graft after Liver Transplantation in Rats.

[Protective effect of glycogen synthase kinase 3β inhibition via peroxisome proliferator-activated receptor alpha activation in mice with acute liver failure].

Effect of N-acetylcysteine on Cardiopulmonary Bypass-Induced Lung Injury in Dogs

Protective effect of adenosine A2A receptor activation in small-for-size liver transplantation.

Inhibition of GSK-3beta ameliorates hepatic ischemia-reperfusion injury through GSK-3beta/beta-catenin signaling pathway in mice

PP2Acα Positively Regulates the Termination of Liver Regeneration in Mice Through the AKT/GSK3β/Cyclin D1 Pathway.